Short communication · 29 Dec 2025
Conference abstractPublished 24 Aug 2015
Epi-genetics and treatment planning for primary glioblastoma
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Background: To establish the frequency of MGMT and RARβ methylation in primary glioblastomas. We screened primary glioblastoma multiforme (GBM) in a population-based study for MGMT and RARβ methylation and correlated them with clinical data and treatment. Results: MGMT methylation was detected in 13 of the 40 patients (32.5%). MGMT-promoter methylation did not correlate with overall survival (OS; p>0.05). RARB methylation was detected in 24 of the 40 patients (60%). The overall survival time of the patients with methylated RARβ was 19 months, and non-methylated RARB was 15 months. There was statically (OS; p<0.05) significance between the patients who were treated with chemotherapy and radiotherapy. Conclusion: In summary, this study is suggested to the RARβ gene is also a new prognostic and predictive candidate marker for the primary GBM patients for choosing therapy strategy. Furthermore MGMT promoter methylation had no prognostic value and lower frequency in primary glioblastomas.
Subjects
Genetics & Molecular BiologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Molecular and Genetic Medicine.
Brief report · 29 Dec 2025
Multi-Omics: Accelerating Biomarker Discovery and Disease Insights
Short communication · 29 Dec 2025
RNA Editing: a Role in Health and Disease
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalMolecular and Genetic Medicine
- SubjectGenetics & Molecular Biology
- BylineArticles whose byline prints “Rasime Kalkan”
